Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1032568-63-0
Drug Levels and Effects
Summary of Use during Lactation
Copanlisib has been removed from the US market. No information is available on the clinical use of copanlisib during breastfeeding. Because copanlisib's half-life is about 39 hours, it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during copanlisib therapy and for 1 month after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Copanlisib
CAS Registry Number
1032568-63-0
Drug Class
Breast Feeding
Milk, Human
Antineoplastic Agents
Enzyme Inhibitors
Signal Transduction Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Molecular modeling strategy for detailing the primary mechanism of action of copanlisib to PI3K: combined ligand-based and target-based approach.[J Biomol Struct Dyn. 2023]Molecular modeling strategy for detailing the primary mechanism of action of copanlisib to PI3K: combined ligand-based and target-based approach.Zhu J, Li X, Meng H, Jia L, Xu L, Cai Y, Chen Y, Jin J, Yu L, Gao M. J Biomol Struct Dyn. 2023 Aug 12; :1-12. Epub 2023 Aug 12.
- Review Regorafenib.[Drugs and Lactation Database (...]Review Regorafenib.. Drugs and Lactation Database (LactMed®). 2006
- Review Alectinib.[Drugs and Lactation Database (...]Review Alectinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Sorafenib.[Drugs and Lactation Database (...]Review Sorafenib.. Drugs and Lactation Database (LactMed®). 2006
- Review Lenvatinib.[Drugs and Lactation Database (...]Review Lenvatinib.. Drugs and Lactation Database (LactMed®). 2006
- Copanlisib - Drugs and Lactation Database (LactMed®)Copanlisib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...